

Isotachophoretic Determination of Glucosamine and Chondroitin Sulphate in Dietary Supplements

ELIŠKA VÁCLAVÍKOVÁ and FRANTIŠEK KVASNIČKA

*Department of Food Preservation, Faculty of Food and Biochemical Technology,
Institute of Chemical Technology Prague, Prague, Czech Republic*

Abstract

VÁCLAVÍKOVÁ E., KVASNIČKA F. (2013): **Isotachophoretic determination of glucosamine and chondroitin sulphate in dietary supplements.** Czech J. Food Sci., **31**: 55–65.

Glucosamine and chondroitin sulfate, components of normal cartilage, are used as ingredients in dietary supplements intended to treat osteoarthritis and/or to support joint health. Of concern is the documented lack of quality in many of the marketed products. We present here a capillary isotachophoretic method for the determination of glucosamine and chondroitin sulfate in dietary supplements. Cationic analysis of glucosamine was performed with a leading electrolyte consisting of 10mM NH₄OH + 20mM acetic acid. As the leading electrolyte for anionic analysis of chondroitin sulphate, a mixture of 5mM HCl + 10mM glycylglycine + 0.05% of 2-hydroxyethylcellulose was used. The solution of 10mM citric acid served as the terminating electrolyte for both glucosamine and chondroitin sulfate analyses. The analytes were detected by conductivity and UV detectors. The characteristics of the method, i.e., linearity, accuracy, repeatability, and quantitation limit, were evaluated. On a set of 35 samples of marketed dietary supplements did we prove that the capillary isotachopheresis is a suitable method for the routine analysis of glucosamine and chondroitin sulfate.

Keywords: capillary isotachopheresis; nutraceuticals; food analysis

Osteoarthritis is the most common degenerative joint disease of the middle-aged and elderly people; the patients affected by this disease suffer from pain and the loss of function. Glucosamine (GA) and chondroitin sulfate (CS) are components of normal cartilage. They are used as ingredients (together or separately) in dietary supplements intended to support the joint health. Due to the increased prevalence of osteoarthritis and the lack of effective therapies, interest is given to the use of these dietary supplements as therapeutic agents for osteoarthritis. Usual daily dose of glucosamine sulphate and chondroitin sulphate is 1500 mg and 1200 mg, respectively (MESSIER *et al.* 2007; BRUYERE *et al.* 2008; JACKSON *et al.* 2010).

There are plenty of such dietary supplements on the marketplace. Of concern is the documented lack of quality in many of the marketed products

both in the finished dosage forms and raw materials (ADEBOWALE *et al.* 2000; BARNHILL *et al.* 2006).

Glucosamine (2-amino-2-deoxy-D-glucose) is the principal component of glycosaminoglycans that form the matrix of connective tissues in the human body. Glucosamine, also known as chitosamine, is the basic monomer of chitin. Chitin is a biopolymer composed of *N*-acetyl-D-glucosamine, which can be found in exoskeletons of invertebrate marine creatures such as oysters, crabs, or shrimps. Glucosamine is usually prepared from chitin by hydrolysis using strong mineral acid (sulphuric or hydrochloric) (MOJARRAD *et al.* 2007). During this reaction, chitin is deacetylated and depolymerised to glucosamine salt of the acid used (Figures 1a–c). The obtained high quality glucosamine hydrochloride is stable, while glucosamine sulfate is not. It is very hygroscopic

Supported by the Ministry of Agriculture of the Czech Republic, Project No. QI91B283, and by the Specific University Research, Project No. MSM 21/2011.




Figure 1. Structural formulas of glucosamine and chondroitin; (a) glucosamine hydrochloride (GA*HCl), MW is 215.64 g/mol, (b) glucosamine sulphate ((GA)₂*H₂SO₄), MW is 456.34 g/mol, (c) glucosamine sulphate potassium chloride ((GA)₂*H₂SO₄*2KCl), MW is 605.54 g/mol, (d) chondroitin sulphate A (CS-A) is the alternative name for chondroitin 4-sulphate, i.e., chondroitin sulphate which is sulphated on the C4 position of the *N*-acetyl-galactosamine, (e) chondroitin sulphate B (CS-B) is the alternative name for dermatan sulphate. It is sulphated on the C4 position of the *N*-acetyl-galactosamine but the C5 of the uronic acid has undergone epimerisation to iduronic acid, (f) chondroitin sulphate C (CS-C) is the alternative name for chondroitin 6-sulphate, which is sulphated on the C6 position of the *N*-acetyl-galactosamine; MW of the disaccharide unit of CS-A, CS-B and CS-C is 443.34 g/mol, $n = 20–200$

and degrades rapidly when exposed to moisture. To overcome this disadvantage, glucosamine sulphate is made from glucosamine hydrochloride by co-crystallisation with potassium or sodium sulphate to yield glucosamine sulphate 2 KCl or 2 NaCl. The content of the glucosamine base (active substance) in glucosamine hydrochloride is 83% (w/w) while in glucosamine sulphate 2 KCl it is only 59% (w/w). Most of the dietary supplements contain glucosamine sulphate 2 KCl rather than glucosamine hydrochloride.

Glucosamine in pharmaceutical formulations, nutraceuticals, and raw bulk materials is determined by HPLC with RI detection (EL-SAHARTY & BARY 2002), evaporative light scattering detection (JACYNO & THRALL 2004), direct UV detection at 195 nm (SHAO *et al.* 2004), and UV detection at 254 nm after derivatisation with phenylisothiocyanate (LIANG *et al.* 1999). Besides HPLC technique, capillary electrophoresis (CE) with UV detection (214 nm) after the derivatisation of GA with anthranilic acid (QI *et al.* 2006) or with conductometric detection (JÁČ *et al.* 2008) without derivatisation have been used. Other described

techniques suitable for the analysis of GA involve spectrophotometry after derivatisation with ninhydrin (WU *et al.* 2005), and high performance thin-layer chromatography (ESTERS *et al.* 2006).

Chondroitin sulphates (Figures 1d–f) are naturally occurring glycosaminoglycans containing disaccharide repeating units formed by hexuronic acid and hexosamine residue. The eminent feature of the molecular structure of CS is the presence of a sulphate ester group in the hexosamine and/or hexuronic acid residue, which gives the CS molecule a highly negative ion charge. CS as a part of proteoglycans is present on the cell surfaces and in the extracellular matrix of almost all animal tissues. It is considered as an important part of the composition of the joint cartilage. Chondroitin sulphate is present in a number of forms; the most common forms are chondroitin sulphate A (Figure 1d), chondroitin sulphate B also known as dermatan sulphate (Figure 1e), and chondroitin sulphate C (Figure 1f). The molecular weight of CS varies between 9000 Da and 93 000 Da (SIM *et al.* 2005). CS is isolated mainly from bovine or porcine cartilage (source of CS-A) and from shark

cartilage as a source of CS-C. The isolation process involves extraction using alkaline solutions or enzymes, alcoholic precipitation, recovery of solids by centrifugation and purification (SCHIRALDI *et al.* 2010). Fish derived CS is currently referred to as the best quality raw material on the market, considering the degree of purity and

sulphation pattern. The identity and quality of CS is the major issue related to its therapeutic activity. Some dietary supplements contain less than the labelled amount of CS, in some cases as little as 10%. Due to the poor CS quality in some nutraceuticals, there is a need for stricter regulations regarding the quality of CS and specific and

Table 1. List of dietary supplements (DS) samples

Sample	Form of DS	Active components	Daily dose			
			form of DS	CS (mg)	GA ¹ (mg)	MSM (mg)
1	tablet	GA*HCl, CS, MSM	2 tablets	500	1500	500
2	tablet	GA*SO ₄ , MSM	3 tablets	–	1415	900
3	capsule	GA*HCl, CS	3 capsules	100	1560	–
4	tablet	GA*SO ₄ , CS	4 tablets	80	100	–
5	tablet	GA*SO ₄ , CS, MSM, HC	3 tablets	600	1415	300
6	capsule	GA*SO ₄ , CS, MSM	6 capsules	400	1 132	1000
7	tablet	GA*SO ₄ , CS, MSM, HA, HC	3 tablets	600	1 415	600
8	tablet	GA*SO ₄ *2 KCl	2 tablets	–	1 516	–
9	tablet	GA*SO ₄ *2 KCl, CS	6 tablets	1200	1071	–
10	tablet	GA*SO ₄ , CS, MSM	3 tablets	1200	1415	540
11	tablet	GA*SO ₄	2 tablets	–	1132	–
12	syrup	CS, HA ²	15 ml	500	–	–
13	powder	GA*SO ₄ , CS, MSM	14 g	400	1415	600
14	capsule	GA*SO ₄ , CS	3 capsules	1200	2264	–
15	capsule	GA*SO ₄ , CS	6 capsules	27	85	–
16	tablet	GA*SO ₄ , CS, MSM	3 tablets	600	1415	900
17	powder	GA*SO ₄ , CS, MSM	10 g	150	755	50
18	powder	GA*HCl	10 g	–	208	–
19	capsule	GA, CS, MSM	3 capsules	100	473	375
20	tablet	GA, CS, HA, HC	1 tablet	75	142	–
21	capsule	GA*SO ₄ , CS	1 capsule	150	660	–
22	tablet	GA, CS, MSM, HC	3 tablets	600	1415	300
23	tablet	GA*HCl, MSM	3 tablets	–	1500	300
24	tablet	GA*SO ₄ *2 KCl, CS, MSM	3 tablets	600	1071	600
25	tablet	GA*HCl, MSM	3 tablets	–	1500	300
26	tablets	GA*HCl, CS, MSM, HC	3 tablets	600	1500	300
27	powder	GA*SO ₄ , CS, HC	6 g	50	1415	–
28	powder	GA*SO ₄ , CS, HC	6 g	50	1415	–
29	tablet	GA*SO ₄ *2 KCl	2 tablets	–	1515	–
30	tablet	GA*SO ₄	2 tablets	–	1509	–
31	powder	GA*HCl, CS, MSM, HA, HC	20 g	150	300	300
32	powder	GA*HCl, CS, MSM, HA, HC	20 g	150	300	300
33	tablet	GA*SO ₄ , CS, MSM	3 tablets	600	1415	900
34	tablet	GA*SO ₄	2 tablets	–	1509	–
35	tablet	GA*HCl, CS, MSM	3 tablets	1200	1500	600

CS – chondroitin sulfate; GA – glucosamine; MSM – methylsulfonylmethane; HA – hyaluronic acid; HC – hydrolysed collagen; GA*HCl – glucosamine hydrochloride; GA*SO₄ – glucosamine sulphate; GA¹ – expressed as glucosamine hydrochloride

accurate analytical procedures to confirm the purity and label claims for both the raw bulk materials and finished products (VOLPI 2009).

The official method mentioned in European Pharmacopoeia concerning the analysis of chondroitin sulphate as a bulk material or as an active principle in pharmaceutical preparations is based on the infrared spectroscopy and electrophoretic identification, and on a photometric titration assay using cetylpyridium chloride (European Pharmacopoeia 2006). The most common spectrophotometric method for the determination of CS in pharmaceuticals and/or nutraceuticals is based on the chromogenic reaction between carbazole and hexuronic acid produced by acid hydrolysis of CS (BITTER & MUIR 1962). It is noteworthy that both the titration and the spectrophotometrical methods can be influenced by the sample matrix of dietary supplements (collagen, hyaluronic acids, etc.) giving usually positively false results. Other, more selective methods, involving size-exclusion chromatography (TOIDA *et al.* 1997; CHOI *et al.* 2003), ion-pair HPLC (JIN *et al.* 2009), and CE (MALAVAKI *et al.* 2008) for the determination of chondroitin sulphate in pharmaceutical and/or nutraceuticals preparations have been reported. Highly selective methods based on enzymic digestion of CS using chondroitinase followed by HPLC (GRØNDHAL *et al.* 2011) or CE (KARAMANOS *et al.* 1995; OKAMOTA *et al.* 2004; MALAVAKI *et al.* 2008) determination of chondroitin disaccharides have been also published.

Capillary isotachopheresis (cITP) equipped with a conductivity detector offers an alternative to the existing methods for the determination of GA and CS in dietary supplements. As far as we know from the literature, the application of cITP has not been

published up to know. That is why we present here a capillary isotachopheretic method for the determination of GA and CS in dietary supplements.

MATERIAL AND METHODS

Chemicals and samples. The standards of glucosamine hydrochloride, chondroitin sulphate A, chondroitin sulphate B, chondroitin sulphate C, chondroitinase ABC, unsaturated chondroitin disaccharides 2-acetamido-2-deoxy-3-O-(4-deoxy- α -L-threo-hex-4-enopyranosyluronic acid)-4-O-sulpho-D-galactose (Δ di-mono4S), and 2-acetamido-2-deoxy-3-O-(4-deoxy- α -L-threo-hex-4-enopyranosyluronic acid)-6-O-sulpho-D-galactose (Δ di-mono6S) were purchased from Sigma-Aldrich (Prague, Czech Republic). The chemicals for the electrolyte preparation, i.e., hydrochloric acid volumetric standard (1 mol/l solution in water), acetic acid volumetric standard (1 mol/l solution in water), ammonium hydroxide volumetric standard (5 mol/l solution in water), glycylglycine (GLYGLY), and 2-hydroxyethylcellulose (HEC) were purchased also from Sigma-Aldrich (Prague, Czech Republic). Citric acid was obtained from Lach-Ner, Ltd. (Neratovice, Czech Republic). All chemicals were of analytical grade. Deionised water of Milli-Q quality (electrical resistivity 18.2 M Ω cm) was used for the electrolyte, standard, and sample preparations. The samples of dietary supplements (Table 1) were obtained from the dietary supplement manufacturers and/or from the domestic market.

Instrumentation. Isotachopheretic analyses were carried with the help of manual column coupling electrophoretic analyser EA 101 with contact con-

Table 2. Conditions of ITP analysis of glucosamine and chondroitin sulphate

	Cationic analysis of glucosamine	Anionic analysis of chondroitin sulphate
Leading electrolyte	10mM NH ₄ OH + 20mM acetic acid	5mM HCl + 10mM GLYGLY + 0.05% HEC
Terminating electrolyte	10mM citric acid	10mM citric acid
Driving current (μ A)		
Preseparation capillary	250	200
Analytical capillary	50 decreased to 25 during detection	50 decreased to 20 during detection
Sample load (μ l)*	ca 30	ca 30
Detection	conductivity and UV at 254 nm	conductivity and UV at 254 nm
Analysis time	15	15

*sample valve with the fixed internal loop; GLYGLY – glycylglycine; HEC – 2-hydroxyethylcellulose

ductivity detectors and a UV detector operating at 254 nm (Villa-Labeco, Spisska Nova Ves, Slovak Republic). The separation compartment of EA 101 analyser consisted of the pre-separation FEP capillary (90 mm × 0.8 mm *i.d.*) coupled with the analytical FEP capillary (90 mm × 0.3 mm *i.d.*). EA 101 was controlled with the help of PC software package ITPPro32 (KasComp Ltd., Bratislava, Slovak Republic) supplied with the analyser. The instrument operates with the hydrodynamically closed separation system (KANIANSKY *et al.* 1997), i.e., electro-osmotic flow is suppressed.

Conditions of analyses, standard and sample preparation. GA and CS in dietary supplements were determined as an anion and a cation, respectively. The conditions of analysis are described in Table 2.

External standard technique (five-point calibration) was used for the quantitative analyses of CS and GA. The calibration solutions of CS (20, 40, 60, 80, and 100 mg/l) were prepared from the stock solution containing 1000 mg of CS/l of demineralised water. The calibration solutions of GA (5, 10, 20, 50, and 100 mg/l) were prepared from the stock solution (1 g/l GA in demineralised water). CS and GA were extracted from the dietary supplements by demineralised water. One tablet, capsule, or recommended dose of powdered or liquid samples was placed (or weighed) into 250-ml volumetric flask and 200 ml of demineralised water was added. The flask was put into an ultrasonic bath (wattage 300 W) for approximately 30 minutes. The extraction was finished when the total disintegration of the tablet was reached. The extract obtained was diluted and filtered (through filter paper) prior to analysis.

Method validation. The cITP method validation was performed according to the International Conference on Harmonization guideline (ICH 1995, 1996) including parameters such as linearity, precision, accuracy, limit of quantitation (LOQ), and limit of detection (LOD). The calibration curves were constructed from the step length vs. concentration of GA and/or CS. Linear regression was applied for the calculation of the intercept, slope, and correlation coefficients of GA and CS calibration curves.

The precision was assessed by the determination of GA and CS (six replicas) in two different samples (including extraction, dilution, and cITP analysis). The intra-day precision was expressed as the relative standard deviation (*RSD* in %) of the analyses of two samples performed within one day. The inter-day precision was expressed as

combined *RSD* (%) of the analyses of two samples performed within two days.

The accuracy of the cITP method was assessed by the determination of GA and CS (three replicas) in a sample spiked with GA and/or CS. The accuracy was expressed as the average recovery (%) of the standard addition at two different levels (50 and 100% additions of the declared concentration of GA and/or CS). For the accuracy and precision measurements, 20 tablets of the sample were triturated in a grinding mortar and thoroughly homogenised. The sample amount corresponding to one tablet was used for the extraction. The spiked samples were prepared by weighing the homogenised sample plus an appropriate amount of GA and/or CS standard into the extraction flask.

The limit of detection (calculated from the calibration equation) corresponds to the concentration of GA and/or CS which gives the minimum detectable zone length equal to one second. The limit of quantitation is calculated as the treble of the detection limit.

RESULTS AND DISCUSSION

GA as a medium-strong base ($pK_a 8 \pm 0.2$) (BLASKÓ *et al.* 1997; JÁČ *et al.* 2008) is protonised (glucosaminium) up to pH 10 and can be determined as a cation within a wide pH range. The effect of pH of the leading electrolyte on the electrophoretic migration of GA was examined in the range 3.5–8 (data not shown). At a low pH (< 4.5), the potential excipients of the dietary supplement (mainly hydrolysed collagen) might interfere with GA. At pH > 6, the separation of GA from the potential interferers was excellent. However, due to the relatively low limiting electrophoretic mobility of GA (comparable to the mobility of tetrabutylammonium cation) problems occurred with selecting sufficiently slow terminating cation. Moreover, the start of the analysis was delayed because the low mobility terminator generates high voltage along the capillary and thus the driving current must be decreased. In view of the costs of both the separation and analysis, we selected 10mM NH_4OH (or KOH) + 20mM acetic acid (pH 4.7) as the optimal leading electrolyte and 10mM citric acid as the terminating electrolyte (hydroxonium is used as terminator). The isotachopherograms of GA standard and the sample No. 33 are shown in Figure 2. It is evident from the conductivity records that GA is fully separated from the sample matrix.

The disaccharide unit of chondroitin contains one carboxylic group ($pK_a \sim 3.3$ (TOMMERAAS & WAHLUND 2009)) and one (or more) *O*-sulphate group ($pK_a \sim -1$). CS is thus a strong poly-acid with a high charge density and is negatively charged even at a low pH (< 3). This property of CS allows performing an electrophoretic separation in acidic electrolytes. We studied the influence of different electrolyte systems in the pH range of 2.5–6 on the electrophoretic mobility of chondroitin sulphates (CS-A, CS-B, and CS-C) and on their separation from common excipients of dietary supplements (data not shown). We found out that the electrolyte system consisting of 5mM HCl + 10mM GLYGLY + 0.05% HEC (pH 3.2) as the leading electrolyte and 10mM citric acid as the terminating electrolyte gave the best results. Under these acidic conditions, the risk of interference of anionic matrix components with CS is minimised. For example, desulphated chondroitin (hyaluronate) as a possible impurity of CS has a lower mobility than the terminator (citrate) and thus does not disturb the analysis. Acesulfam K and a high content of hydrolysed col-

lagen (> 10 g/100 g) were the only interferences that we met. Acesulfam K migrates very closely to CS, however, it can be easily detected in the UV trace due to its strong absorption at 254 nm. Hydrolysed collagen is positively charged at a low pH and is able to form a complex with chondroitin and to decrease its mobility resulting in the absence of CS step in the isotachopherogram. The problem with collagen can be solved by performing the analysis at a higher pH. For example, collagen is not highly protonised at pH 6 (very weak complex with chondroitin) and CS is separated and determined. However, at this pH a risk occurs of CS interference with other excipients or non-chondroitin polysaccharides.

The isotachopherograms of the blank analysis and standards of CS-A, CS-B, and CS-C are depicted in Figures 3a–d. All the CS standards tested had almost identical mobilities (similar step heights on the conductivity record) due to similar charge densities (number of sulphate groups per disaccharide unit) and thus could not be separated by cITP method. The molecular weight of CS has a negligible influence on




Figure 2. Isotachopherograms of blank, glucosamine standard and sample; trace from the conductivity (black) and the UV (254 nm) detector (gray) of the analytical capillary, respectively: (a) isotachopherogram blank (deminerallized water); (b) isotachopherogram of glucosamine standard (20 mg/l); (c) isotachopherogram of dietary supplement sample No 33 (1 tablet/250 ml, 50× diluted, ca 150 μ mol GA/l)




Figure 3. Isotachopherograms of blank, chondroitin standard and sample; trace from the conductivity (black) and the UV (254 nm) detector (grey) of the analytical capillary, respectively

(a) isotachopherogram of blank (demineralized water), (b) isotachopherogram of standard of CS-A (100 mg/l)

(c) isotachopherogram of standard of CS-B (100 mg/l), (d) isotachopherogram of standard of CS-C (100 mg/l)

(e) isotachopherogram of standard mixture of CS-A (40 mg/l) and chondroitin disaccharides Δ di-mono4S and Δ di-mono6S, (each 10 mg/l), (f) isotachopherogram of standard of CS-A (100 mg/l) after digestion by chondroitinase ABC

the electrophoretic mobility of CS (MALAVAKI *et al.* 2008). It is clear from the UV trace (Figures 3b–d) that all Sigma CS standards contain “impurities”

absorbing at 254 nm. UV spectrum of “impurities” has a broad maximum at 228–236 nm (data not shown). It led us to the presumption that the im-

purities could be unsaturated oligosaccharides (up to deca-saccharides) as products of partial enzymic cleavage of chondroitin sulphate by chondroitinase formed within the isolation or purification of chondroitin sulphate (ZHANG *et al.* 2009). Chondroitinase cleaves the $1\beta \rightarrow 4$ glycosidic bonds between *N*-acetylgalactosamine and uronic acid of CS and releases unsaturated oligosaccharides strongly absorbing UV light. The final products of the cleavage are variously sulphated disaccharides depending on the original CS (SAITO *et al.* 1968). CS-A and CS-B give Δ di-mono4S while CS-C gives Δ di-mono6S.

The isotachopherogram of a mixture of CS-A, Δ di-mono4S, and Δ di-mono6S (Figure 3e) clearly shows that chondroitin is separated from these disaccharides. The hydrolysis product of CS-A is shown in Figure 3f. It is evident from this record that there is no step of chondroitin and/or “impurities”. It confirms our hypothesis that “impurities” are unsaturated oligosaccharides. Furthermore, from the record is clear that the standard of CS-A is a mixture of CS-C and CS-A. It contains both Δ di-mono4S and Δ di-mono6S. The skewed steps of disaccharides are due to the anomeric forms of hexosamines present at the reducing end of chondroitin disaccharides. These α - and β -anomers are not fully separated under the given conditions. In the isotachopherogram

another step (UV absorbing) is present with the electrophoretic mobility higher than that of the original CS (lower step height). This probably represents disaccharides with more than one sulphate groups in their molecules. Phosphate migrating between CS and disaccharides comes from chondroitinase ABC.

Validation of cITP determination of GA

The validation was carried out under optimal conditions (Table 2) using standard solution of GA (10–100 mg/l) and selected samples of dietary supplements (33 and 34). The values of the characteristics of cITP method are summarised in Table 3. The cITP method is characterised by excellent linearity ($r > 0.999$), good precision ($RSD = 1.82\%$), high accuracy (recovery $98.8 \pm 1.7\%$), and high sensitivity (LOQ = 2.4 mg/l). We applied cITP for the analyses of dietary supplements samples. Some of them were obtained directly from a manufacturer; some were purchased on the domestic market. The results of analyses of 33 samples are summarised in Figure 4a. The GA content found was expressed as the percentage of the declared content of the labelled form of GA. Only 21 samples (64%) contained more than

Table 3. Method characteristics of isotachopheretic determination of GA and CS

Characteristic	GA value	CS value
RSH (–)	0.79 ± 0.02	0.42 ± 0.02
Precision (RSD in %)		
Intra-day ¹	1.82	1.53
Inter-day ²	1.67	1.94
Accuracy (% recovery) ³	98.8 ± 1.7	99.7 ± 2.6
Linearity (mg/l)	10–100	20–200
Intercept (mg/l)	0.2 ± 0.4	1.9 ± 0.7
Slope (mg/l/s)	0.555 ± 0.005	1.34 ± 0.01
Correlation coefficient	0.9999	0.9999
Limit of detection (mg/l) ⁴	0.8	3
Limit of quantitation (mg/l) ⁵	2.4	9

RSH – relative step height; it is average value from calibration analyses (for GA) and from the analyses of CS-A, CS-B and CS-C (for Cs); ¹analysis of sample No 33 and 34 within one day ($n = 6$); analysed concentration of GA was ca 20 mg/l and 30 mg/l and analysis of sample No 16 and No 35 within one day ($n = 6$); analysed concentration of CS was 80 and 60 mg/l; ²analysis of sample No 33 and 34 for GA and sample No. 16 and No. 35 for CA within two days ($n = 12$); ³analysis of sample No 33; analysed concentration of GA was ca 20 mg/l; 50 and 100% standard addition, i.e., 10 and 20 mg/l and analysis of sample 16; analysed concentration of CS was 40 mg/l; 50 and 100 % standard addition (CS-A), i.e., 20 and 40 mg/l; ⁴calculated as a minimal detectable step length (1 s); ⁵calculated as the treble of the limit of detection




Figure 4. Results of ITP analyses of food supplements sample; found concentration of GA (a) and CS (b) was expressed as a percentage of the declared content

90% of the declared amount of GA. In our opinion, the incorrectly labelled form of GA is the main reason for such findings. Only a few samples were labelled with the proper form of GA, e.g., glucosamine hydrochloride or glucosamine sulphate*2 KCl. Most of the samples stated to contain glucosamine sulphate, but actually glucosamine sulphate*2 KCl had been used. As we mentioned before, glucosamine sulphate is an unstable substance and that is why this form is not used. The differences in GA content are great because of great differences in molecular weight (Figure 1). If we recalculated the content of GA as $(GA)_2$ sulphate*2 KCl, more than 90% of the samples would be satisfactory. It is noteworthy that in such case the customer buys mineral salts at the price of glucosamine.

Validation of cITP determination of CS

The characteristics of the method of CS determination using cITP were evaluated in the same way as in the case of GA. The calculated parameters are based on the results of the analyses carried out under optimal conditions (Table 2) using standard solution of CS-A (20–200 mg/l) and selected samples of dietary supplements (16 and 35). The results obtained are summarised in Table 3. The method is characterised by excellent linearity ($r > 0.999$), good precision ($RSD = 1.94\%$), high accuracy (recovery $99.7 \pm 2.6\%$), and high sensitivity ($LOQ = 9$ mg/l). The results of the analyses of 22 samples are summarised in Figure 4b. The CS content found was expressed as the percentage of

the labelled content of CS. Only 6 samples (27%) contained more than 90% of the declared amount of CS. Chondroitin raw material of a low quality is the main reason for such results.

CONCLUSIONS

We presented cITP method for the determination of glucosamine and chondroitin in raw materials and dietary supplements such as tablets, capsules or liquid formulations. The developed methods were validated according to ICH guideline. The presented results show that cITP method fulfils general requirements for analytical methods and is thus suitable for the analysis of glucosamine and chondroitin in both raw material and dietary supplements. Low laboriousness (water extraction and filtration only) and low running costs are the important features of cITP methods especially for routine analyses. The cITP can be an expedient alternative to HPLC or CZE.

References

- ADEBOWALE A.O., COX D.S., LIANG Z., EDDINGTON N.D. (2000): Analysis of glucosamine and chondroitin sulfate content in marketed products and the Caco-2 permeability of chondroitin sulfate raw materials. *Journal of the American Nutraceutical Association*, **3**: 37–44.
- BARNHILL J.G., FYE C.L., WILLIAMS D.W., REDA D.J., HARRIS C.L., CLEGG D.O. (2006): Chondroitin product selection for the glucosamine/chondroitin arthritis intervention trial. *Journal of the American Pharmacists Association*, **46**: 14–24.
- BITTER T., MUIR H.M. (1962): A modified uronic acid carbazole reaction. *Analytical Biochemistry*, **4**: 330–334.
- BLASKÓ A., BUNTON C.A., BUNEL S., IBARRA C., MORAGA E. (1997). Determination of acid dissociation constants of anomers of amino sugars by ^1H NMR spectroscopy. *Carbohydrate Research*, **298**, 163–172.
- BRUYERE O., PAVELKA K., ROVATI, L.C., GATTEROVÁ J., GIACOVELLI G., OLEJÁROVÁ M., DEROISY R., REGINSTER J.Y. (2008): Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomized, placebo-controlled trials. *Osteoarthritis Cartilage*, **16**: 254–260.
- CHOI D.W., KIM M.J., KIM H.S., CHANG S.H., JUNG G.S., SHIN K.Y., CHANG S.Y. (2003): A size-exclusion HPLC method for the determination of sodium chondroitin sulphate in pharmaceutical preparations. *Journal of Pharmaceutical and Biomedical Analysis*, **31**: 1229–1236.
- Chondroitin sulphate sodium (2006). *European Pharmacopoeia*. 5th Ed. 4206–4208.
- EL-SAHARTY Y.S., BARY A.A. (2002): High-performance liquid chromatographic determination of nutraceuticals, glucosamine sulphate and chitosan, in raw materials and dosage forms. *Analytica Chimica Acta*, **462**: 125–131.
- ESTERS V., ANGENOT L., BRANDT V., FRÉDÉRICH M., TITS M., VAN NERUM C., WAUTERS J.N., HUBERT P. (2006): Validation of a high-performance thin-layer chromatography/densitometry method for the quantitative determination of glucosamine in a herbal dietary supplement. *Journal of Chromatography A*, **1112**: 156–164.
- GRØNDHAL F., TVEIT H., AKSLEN-HOEL L.K., PRYDZ K. (2011): Easy HPLC-based separation and quantitation of chondroitin sulphate and hyaluronan disaccharides after chondroitinase ABC treatment. *Carbohydrate Research*, **346**: 50–57.
- International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use (1995): Validation of Analytical Procedures. ICH-Q2A, Geneva.
- International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use (1996): Validation of Analytical Procedures: Methodology. ICH-Q2B, Geneva.
- JACYNO M., THRALL C. (2004): A high sensitivity HPLC assay for glucosamine using evaporative light scattering detection. *LC-GC North America*, **22** (Suppl): 49.
- JACKSON C.G., PLAAS A.H., SANDY J.D., HUA C., KIM-ROLANDS S., BARNHILL J.G., HARRIS C.L., CLEGG D. O. (2010): The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. *Osteoarthritis Cartilage*, **18**: 297–302.
- JÁČ P., LOS P., SPÁČIL Z., POSPÍŠILOVÁ M., POLÁŠEK M. (2008): Fast assay of glucosamine in pharmaceuticals and nutraceuticals by capillary zone electrophoresis with contactless conductivity detection. *Electrophoresis*, **29**: 3511–3518.
- JIN P., MA J., WU X., ZOU D., SUN C., X. HU X. (2009): Simultaneous determination of chondroitin sulfate sodium, allantoin and pyridoxine hydrochloride in pharmaceutical eye drops by an ion-pair high-performance liquid chromatography. *Journal of Pharmaceutical and Biomedical Analysis*, **50**: 293–297.
- KANIANSKY D., MARÁK J., MASÁR M., IVÁNYI F., MADAJOVÁ V., ŠIMUNIČOVÁ E., ZELENSKÁ V. (1997): Capillary zone electrophoresis in a hydrodynamically closed separation system with enhanced sample loadability. *Journal of Chromatography A*, **772**: 103–114.
- KARAMANOS N.K., AXELSSON S., VANKY P., TZANAKAKIS G.N., HJERPE A. (1995): Determination of hyaluronan and

- galactosaminoglycan disaccharides by high-performance capillary electrophoresis at the attomole level. Applications to analyses of tissue and cell culture proteoglycans. *Journal of Chromatography A*, **696**: 295–305.
- LIANG Z., LESLIE J., ADEBOWALE A., ASHRAF M., EDDINGTON N.D. (1999): Determination of the nutraceutical, glucosamine hydrochloride, in raw materials, dosage forms and plasma using pre-column derivatization with ultraviolet HPLC. *Journal of Pharmaceutical and Biomedical Analysis*, **20**: 807–814.
- MALAVAKI C.J., ASIMAKOPOULOU A.P., LAMARI F.N., THEOCHARIS A.J., TZANAKAKIS G.N., KARAMANOS N.K. (2008): Capillary electrophoresis for the quality control of chondroitin sulfates in raw materials and formulations. *Analytical Biochemistry*, **374**: 213–220.
- MESSIER S.P., MIHALKO S., LOESER R.F., LEGAULT C., JOLLA J., PFRUENDER J., PROSSER B., ADRIAN A., WILLIAMSON J.D. (2007): Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. *Osteoarthritis Cartilage*, **15**: 1256–1266.
- MOJARRAD J.C., NEMATI M., VALIZAHED H., ANSARIN M., BOURBOUR S. (2007): Preparation of glucosamine from exoskeleton of shrimp and predicting production yield by response surface methodology. *Journal of Agricultural and Food Chemistry*, **55**: 2246–2250.
- OKAMOTA H., NAKAJIMA T., ITO Y., SHIMADA K., YAMATO S. (2004): Development of a novel analytical method for determination of chondroitin sulfate using an in-capillary enzyme reaction. *Journal of Chromatography A*, **1035**: 137–144.
- QI L., ZHANG S.F., CHEN M.Y. (2006): Capillary electrophoretic determination of glucosamine in osteoarthritis tablets via microwave-accelerated dansylation. *Journal of Pharmaceutical and Biomedical Analysis*, **41**: 1620–1624.
- SAITO H., YAMAGATA T., SUZUKI S. (1968): Enzymatic methods for the determination of small quantities of isomeric chondroitin sulfates. *Journal of Biological Chemistry*, **243**: 1536–1542.
- SCHIRALDI C., CIMININ D., DE ROSA M. (2010): Production of chondroitin sulfate and chondroitin. *Applied Microbiology and Biotechnology*, **87**: 1209–1220.
- SHAO Y., ALLURI R., MUMMERT M., KOETTER U., LECH S. (2004): A stability-indicating HPLC method for the determination of glucosamine in pharmaceutical formulations. *Journal of Pharmaceutical and Biomedical Analysis*, **35**: 625–631.
- SIM J.S., JUN G., TOIDA T., CHO S.Y., CHOI D.W., CHANG S.Y., LINDHARDT R.J., KIM, Y.S. (2005): Quantitative analysis of chondroitin sulfate in raw materials, ophthalmic solutions, soft capsules and liquid preparations. *Journal of Chromatography B*, **818**: 133–139.
- TOIDA T., SHIMA M., AZUMAYA S., MARUYAMA T., TOYODA, H., IMANARI T., LINHARDT R.J. (1997): Detection of glycosaminoglycans as a copper(II) complex in high-performance liquid chromatography. *Journal of Chromatography A*, **787**: 266–270.
- TOMMERAAS K., WAHLUND P.O. (2009): Poly-acid properties of biosynthetic hyaluronan studied by titration. *Carbohydrate Polymers*, **77**: 194–200.
- VOLPI N. (2009): Quality of different chondroitin sulfate preparations in relation to their therapeutic activity. *Journal of Pharmacy and Pharmacology*, **61**: 1271–1280.
- WU Y., HUSSAIN M., FASSIHI R. (2005): Development of a simple analytical methodology for determination of glucosamine release from modified release matrix tablets. *Journal of Pharmaceutical and Biomedical Analysis*, **38**: 263–269.
- ZHANG Z., YOUMIE PARK Y., KEMP M. M., ZHAO W., IM A., SHAYA D., CYGLER M., KIM Y. S., LINHARDT R.J. (2009): LC-MS to study chondroitin lyase action pattern. *Analytical Biochemistry*, **385**: 57–64.

Received for publication March 6, 2012
Accepted after corrections June 26, 2012

Corresponding author:

Prof. Ing. FRANTIŠEK KVASNIČKA, CSc., Vysoká škola chemicko-technologická v Praze, Fakulta potravinářské a biochemické technologie, Ústav konzervace potravin, Technická 5, 166 28 Praha 6, Česká republika; E-mail: frantisek.kvasnicka@vscht.cz
